...encapsulating rapamycin. Resolve's autoimmune therapy reduces fatigue in Phase II Sjögren’s trial Also at EULAR, Resolve Therapeutics LLC...
...Trazenta, linagliptin (BI 1356) Boehringer Ingelheim GmbH Bone Therapeutics S.A. Eli Lilly and Co. Follica Inc. Idorsia Ltd. Nektar Therapeutics PureTech Health plc Resolve Therapeutics LLC Roche Savara...

...licensing agreement in 2016, also signed licensing deal with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2017 Resolve Therapeutics LLC...

...other preclinical compounds to treat SLE and other autoimmune diseases (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...

...exercisable after completion of the Phase II trial in SLE (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...

...exercisable after completion of the Phase IIa trial in SLE (see BioCentury, March 4, 2013). Resolve Therapeutics LLC...

...composed of cellular debris, including autoantibodies and nucleic acids. Fenwick & West LLP advised Resolve. Resolve Therapeutics LLC...

...U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Genentech Inc. , South San Francisco, Calif. Resolve Therapeutics LLC...
...Seattle, Wash. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Washington , Seattle, Wash. Sidebars Resolve Therapeutics LLC...

...5/17/11 Type: Venture financing Raised: $2 million Investors: New Science Ventures; Easton Capital Investment Note: Resolve Therapeutics...